| Name | Title | Contact Details |
|---|---|---|
Jessica Meng |
Chief Commercial Officer | Profile |
Doug Schenkel |
Chief Financial Officer | Profile |
Akash Patel |
Director, Financial Planning and Analysis | Profile |
Monique Cadle |
Vice President of People | Profile |
Victor Velculescu |
Founder and Chief Executive Officer | Profile |
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O`Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.
We build with carbon the same way nature does. Our biocement® materials are healthier for us and the Planet.
Cardiome Pharma Corp. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform from the ground up in the U.S. and China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community.
Avectas is a cell engineering technology business developing a unique delivery platform to enable the ex vivo manufacture of gene-modified cell therapy products, which will retain high in vivo functionality. Our vision is to position the non-viral SOLUPORE® cell engineering technology to be integrated into manufacturing processes for multiple autologous and allogeneic therapies and commercialised through development and license agreements.